Format

Send to

Choose Destination
Int J Hematol. 2011 Apr;93(4):458-464. doi: 10.1007/s12185-011-0825-8. Epub 2011 Apr 8.

Vitamin B12 deficiency, hyperhomocysteinemia and thrombosis: a case and control study.

Author information

1
Department of Hematology, Complejo Hospitalario Toledo, Hospital Virgen de la Salud, Avenida Barber 30, 45004, Toledo, Spain. aremacha@sescam.jccm.es.
2
Department of Hematology, Hospital de Sant Pau, Barcelona, Spain.
3
Department of Biochemistry, Hospital de Sant Pau, Barcelona, Spain.
4
Department of Neurology, Hospital de Sant Pau, Barcelona, Spain.
5
Department of Cardiology, Hospital de Sant Pau, Barcelona, Spain.
6
Department of Hematology, Complejo Hospitalario Toledo, Hospital Virgen de la Salud, Avenida Barber 30, 45004, Toledo, Spain.

Abstract

This study aimed at assessing the relationship between thrombosis, hyperhomocysteinemia and vitamin B12 deficiency using a case-control study carried out in 326 patients with thrombosis (case group) and 351 patients from the same hospital (control group). Apart from the classic risk factors, a number of hematological variables were evaluated, including serum vitamin B12 (B12), red cell folate (RCF), and serum homocysteine (Hcy). An evaluation of serum methylmalonic acid (MMA) and a clinical study were carried out to investigate B12 pathology. Results of univariate analysis demonstrated decreased B12 levels in thrombosis (Student's t test, p < 0.0001). Vitamin B12 below 200 pmol/l (LB200) or below 150 pmol/l (LB150), and red cell folate below 600 nmol/l were found in 17.2, 8.6, and 2.2% of cases with thromboembolism, respectively. An increase in Hcy was detected in 86 cases with thrombosis (26.3%). An abnormality in vitamin B12 and/or renal function was found in 80% of cases with hyperHcy and thrombosis. The MMA increase demonstrated that vitamin B12 deficiency was present in these patients with low levels of vitamin B12 in serum, and the MMA levels were in concordance with Hcy levels. The clinical study revealed B12 malabsorption in most cases with LB200. Multivariate analysis showed that serum vitamin B12 (RR 0.998, CI 0.997-0.999) was moderately related to thromboembolism. The results indicated that vitamin B12 deficiency was common among patients with hyperhomocysteinemia and thrombosis. Moreover, HyperHcy was caused by vitamin B12 deficiency and/or chronic renal failure in most patients with thrombosis. As the main cause of vitamin B12 deficiency was vitamin malabsorption, parenteral vitamin B12 with or without folic acid should be administered for the treatment of this condition. However, it remains to be demonstrated whether this treatment approach prevents recurrent thromboses in patients with vitamin B12 deficiency and thrombosis, as suggested by some case reports.

PMID:
21475950
DOI:
10.1007/s12185-011-0825-8
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center